Monday, 22 October 2018
Latest news
Main » Sage Therapeutics (SAGE) PT Raised to $280.00

Sage Therapeutics (SAGE) PT Raised to $280.00

08 December 2017

SAGE Therapeutics has $145.0 highest and $18 lowest target. 30 funds opened positions while 53 raised stakes. Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) has declined 27.09% since December 7, 2016 and is downtrending. SAGE Therapeutics has a 1-year low of $26.55 and a 1-year high of $75.49. Northwestern Mutual Wealth Mgmt Co holds 34 shares or 0% of its portfolio. BlackRock Institutional Trust Company N.A. now owns 681,592 shares of the biopharmaceutical company's stock worth $31,387,000 after buying an additional 190,065 shares in the last quarter. (NASDAQ:SAGE). Parametric Portfolio Assoc Ltd Limited Liability Company holds 0% or 22,535 shares in its portfolio.

At day 15, 64 percent of patients who received SAGE-217 achieved remission, defined as a score of seven or less on the HAM-D scale, compared with 23 percent of patients who received a placebo (p=0.0005). The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.09. The Massachusetts-based Essex Mngmt Communication Lc has invested 0.36% in Sage Therapeutics, Inc.

The stock increased 74.90% or $68.83 during the last trading session, reaching $160.73. The firm earned "Buy" rating on Tuesday, September 12 by Canaccord Genuity. It has outperformed by 99.75% the S&P500. The company has market cap of $6.60 billion. The rating was maintained by Leerink Swann with "Buy" on Tuesday, June 20. The 12-month average price target assigned to the stock is $116.67, which represents a potential upside of 27% from where the stock is now trading. The company presently has an average rating of "Buy" and an average price target of $121.86. (NASDAQ:SAGE). Nicholas Prtn L P invested 0.43% of its portfolio in Sage Therapeutics, Inc. Teachers Retirement Systems Of The State Of Kentucky invested in 0.03% or 32,776 shares. (NASDAQ:SAGE) has "Buy" rating given on Thursday, November 16 by Bank of America. Jefferies Grp Limited Liability Co reported 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). At the time of writing, the First Call consensus price target for the company is $114.07. Palo Alto Invsts Ltd Liability Corporation holds 3.84% or 1.03 million shares in its portfolio. Sectoral Asset Management Incorporated owns 0.11% invested in Sage Therapeutics, Inc. Oppenheimer Asset accumulated 0% or 379 shares. BMO Capital Markets maintained Sage Therapeutics, Inc. Lake Street initiated the shares of SAGE in report on Friday, March 11 with "Buy" rating.

Sentiment on the street is mostly bullish on SAGE stock. (NASDAQ:SAGE) news were published by: which released: "Sage Therapeutics shares soar after postpartum depression drug meets main goal" on November 09, 2017. It's hard to understate how meaningful these data are in the backdrop of the very significant unmet medical need in depression: even if the SAGE data on a placebo-adjusted basis weren't differentiated via cross-trial comparisons, we still think '217 would be an important drug as it offers a new mechanism (extra-synaptic GABA-modulation) in an area where the vast majority of options generally modulate the same pathways (serotonin, dopamine, norepinephrine).

Palestinians say they won't meet with Pence
Rajoub also signalled that Abbas would not meet with Pence during his planned visit later this month. President Donald Trump's announcement that he was recognizing the city as Israel's capital.

SAGE Therapeutics Inc. (NASDAQ: SAGE) shares rocketed by as much as 79 percent after it had reported successful results from its mid-stage clinical trial for its depression drug.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Sage Therapeutics (SAGE) PT Raised to $280.00